Old West Investment Management LLC acquired a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 47,465 shares of the biopharmaceutical company’s stock, valued at approximately $471,000.
A number of other large investors have also recently added to or reduced their stakes in FOLD. Wellington Management Group LLP lifted its holdings in shares of Amicus Therapeutics by 101.9% in the fourth quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after purchasing an additional 7,666,335 shares in the last quarter. Norges Bank purchased a new stake in Amicus Therapeutics in the 4th quarter valued at approximately $35,915,000. Blackstone Inc. acquired a new stake in Amicus Therapeutics during the 4th quarter valued at $35,008,000. Janus Henderson Group PLC grew its holdings in Amicus Therapeutics by 20.1% during the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after buying an additional 2,307,385 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund increased its position in Amicus Therapeutics by 583.4% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,176,600 shares of the biopharmaceutical company’s stock worth $25,640,000 after buying an additional 1,858,100 shares in the last quarter.
Amicus Therapeutics Trading Down 2.1 %
FOLD stock opened at $11.06 on Tuesday. Amicus Therapeutics, Inc. has a 52 week low of $9.02 and a 52 week high of $14.57. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -22.57 and a beta of 0.69. The company has a quick ratio of 2.26, a current ratio of 2.75 and a debt-to-equity ratio of 2.93. The business has a fifty day simple moving average of $10.98 and a 200-day simple moving average of $10.76.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on FOLD. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Wells Fargo & Company initiated coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research note on Friday, August 16th. Finally, Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 target price for the company. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.
Read Our Latest Report on FOLD
Insiders Place Their Bets
In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total value of $77,550.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,168,002.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the transaction, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,866,540. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $9,168,002.36. The disclosure for this sale can be found here. Insiders sold a total of 21,100 shares of company stock worth $226,375 over the last ninety days. 2.20% of the stock is owned by company insiders.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
- Five stocks we like better than Amicus Therapeutics
- 3 Monster Growth Stocks to Buy Now
- Why Zillow Group Could Soar with the Upcoming Interest Rate Cuts
- Why Invest in 5G? How to Invest in 5G Stocks
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Consumer Discretionary Stocks Explained
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.